abstract
INTRODUCTION:
Late-stage
ovarian cancer patient's survival depends on complete cytoreduction and
chemotherapy. Complete cytoreduction is more often achieved in
institutions with a case volume of >20 cases per year. The Integrated
care program Ovar (IgV Ovar) was founded in 2005 and started recruiting
in 2006 with 21 health insurances and six expert centers of ovarian
cancer treatment as a quality initiative. Results of the pilot and
outcomes of patients of three participating centers will be presented
here.
METHODS:
Data
of 1038 patients with ovarian cancer were collected. Adjuvant patients
(n = 505) stage FIGO IIB-IV (n = 307) were analyzed for cytoreduction
and survival. FIGO IIIC patients were analyzed separately.
RESULTS:
Median
follow-up was 32.7 months. Progression-free survival (PFS) was
23.1 months and overall survival (OS) was 53.6 months for stage
IIB-IV.
Patients with FIGO IIIC were completely cytoreduced in 48 %. PFS was 21,
29 months if completely cytoreduced. OS was 47.4, 64.9 months if
completely cytoreduced.
DISCUSSION:
Although
the IgV Ovar Rhineland proved to have some structural problems with
recruitment and prospective data collection, cytoreduction rates and
outcome of patients prove treatment of patients in
expert centers is
superior to the national and international mean. Therefore, a new
quality initiative will be started to bring more awareness to women and
to their gynecologists and general practitioners of just how important a
good referral strategy is.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.